Mizuho Begins Coverage of Apogee Therapeutics (APGE) with a Positive Outlook
Mizuho Coverage Initiation: Mizuho initiated coverage of Apogee Therapeutics (NasdaqGM:APGE) on October 21, 2025, with an "Outperform" recommendation, suggesting a potential upside of 71.00% based on an average price target of $95.54/share.
Institutional Ownership Trends: As of the last quarter, 405 funds reported positions in Apogee Therapeutics, with a slight increase in ownership but a significant decrease in total shares owned by institutions by 18.40%.
Analyst Price Forecast: The price forecasts for Apogee Therapeutics range from a low of $60.60 to a high of $121.80, indicating a bullish sentiment with a put/call ratio of 0.56.
Shareholder Activity: Notable shareholders include VR Adviser with 16.01% ownership, while Wellington Management significantly reduced its stake by 44.15%, indicating varied strategies among institutional investors.
Trade with 70% Backtested Accuracy
Analyst Views on APGE
About APGE
About the author
Affinity Asset Advisors Increases Stake in Apogee Therapeutics
- Increased Holdings: Affinity Asset Advisors disclosed a purchase of 61,500 shares of Apogee Therapeutics during Q4 2025, with an estimated trade value of $3.87 million, indicating strong confidence in the company.
- Value Appreciation: Following this acquisition, Affinity's total stake in Apogee reached 1,234,926 shares, with a value increase of $46.59 million, reflecting an impressive 86.9% rise in the company's stock price over the past year.
- Portfolio Concentration: Apogee now constitutes 6.9% of Affinity's total assets under management, ranking as the top holding among its five largest positions, showcasing significant trust in its monoclonal antibody pipeline.
- Outstanding Market Performance: Apogee's stock delivered an alpha of 75.14 percentage points over the S&P 500, underscoring its robust performance in the biotechnology sector and potential for future growth.
Apogee Therapeutics (APGE.US) Officer Plans to Sell $3.84 Million in Common Stock via Form 144
Stock Sale Announcement: Henderson Michael Thomas plans to sell 60,000 shares of Apogee Therapeutics common stock on February 11, with an estimated market value of approximately $3.84 million.
Reduction in Shareholding: Thomas has reduced his shareholding in Apogee Therapeutics by 80,000 shares since December 4, 2025, with a total value of around $6.13 million.
Apogee Therapeutics (APGE) Options Volume Surges 46.6% Today
- Active Options Trading: Apogee Therapeutics has seen an options volume of 4,166 contracts today, equating to approximately 416,600 shares, indicating a trading activity level of 46.6% of its average daily volume over the past month.
- High Demand Options: Notably, the $90 strike call option expiring on March 20, 2026, has seen a significant volume of 2,505 contracts traded today, representing about 250,500 shares, reflecting strong market interest at this strike price.
- Ceva Inc Options Activity: Concurrently, Ceva Inc has recorded an options volume of 1,294 contracts today, approximately 129,400 shares, which corresponds to 45.8% of its average daily trading volume over the past month.
- Increased Interest in Strike Price: Among Ceva's options, the $30 strike call option expiring on February 20, 2026, has seen a trading volume of 506 contracts today, representing around 50,600 shares, indicating a rising market focus on this strike price.
Stocks to Consider Buying in 2026: Insights from Our Roundtable Experts, Including DoorDash and LVMH
Stock Picks Overview: The second installment of the 2026 Barron’s Roundtable features 30 stock picks from five investment experts, highlighting both well-known companies and lesser-known options.
Familiar Names Included: Among the stock picks are recognizable brands such as Home Depot, Starbucks, and Nike, indicating a mix of established and emerging investment opportunities.
Biodegradable Innovation: The article hints at a British company that has recently acquired a manufacturer of biodegradable sneaker midsoles, showcasing a trend towards sustainable products in the footwear industry.
Investment Insights: The Roundtable serves as a platform for sharing diverse investment strategies and insights, appealing to both seasoned investors and those looking to explore new market trends.
Apogee Therapeutics CMO Sells $1.46 Million in Shares
- Share Sale: Carl Dambkowski, CMO of Apogee Therapeutics, sold 18,700 shares for approximately $1.46 million, reducing his direct holdings by 8.09% from 231,223 to 212,523 shares, indicating a structured liquidity management approach.
- Option Exercise: Prior to the sale, Dambkowski exercised 14,025 stock options, maintaining a substantial stake worth about $16.8 million, which reflects his ongoing confidence in the company's future prospects.
- Market Performance: Apogee Therapeutics shares have surged approximately 60% over the past year, significantly outperforming the S&P 500's 18% gain, indicating growing market confidence in its immunology pipeline and competitive positioning in the biotech sector.
- Financial Position: As of the third quarter, Apogee reported $913 million in cash and cash equivalents, ensuring funding through the second half of 2028, which supports its strategic development in clinical-stage biologics.
Apogee Therapeutics CMO Sells $1.46 Million in Shares Following Options Exercise
- Significant Transaction Size: Apogee Therapeutics' CMO Carl Dambkowski sold 18,700 shares for a total value of $1.46 million on Wednesday, which is substantially larger than his recent median sale size of 3,690 shares, highlighting the impact of the options exercise on transaction scale.
- Options Exercise and Sale: The transaction involved exercising 14,025 options and immediately selling 18,700 shares, indicating a structured liquidity event following a strong market performance rather than a signal of clinical confidence in the company.
- Stable Equity Holdings: Post-transaction, Dambkowski retains 212,523 shares valued at approximately $16.8 million, demonstrating continued confidence in the company despite the large sale.
- Company Financial Health: Apogee Therapeutics has a market capitalization of $5.3 billion and a 60% stock price increase over the past year, reflecting strong market confidence in its immunology pipeline, while closing the third quarter with $913 million in cash and equivalents, ensuring funding for future needs.
Affinity Asset Advisors Increases Stake in Apogee Therapeutics
- Increased Holdings: Affinity Asset Advisors disclosed a purchase of 61,500 shares of Apogee Therapeutics during Q4 2025, with an estimated trade value of $3.87 million, indicating strong confidence in the company.
- Value Appreciation: Following this acquisition, Affinity's total stake in Apogee reached 1,234,926 shares, with a value increase of $46.59 million, reflecting an impressive 86.9% rise in the company's stock price over the past year.
- Portfolio Concentration: Apogee now constitutes 6.9% of Affinity's total assets under management, ranking as the top holding among its five largest positions, showcasing significant trust in its monoclonal antibody pipeline.
- Outstanding Market Performance: Apogee's stock delivered an alpha of 75.14 percentage points over the S&P 500, underscoring its robust performance in the biotechnology sector and potential for future growth.
Apogee Therapeutics (APGE.US) Officer Plans to Sell $3.84 Million in Common Stock via Form 144
Stock Sale Announcement: Henderson Michael Thomas plans to sell 60,000 shares of Apogee Therapeutics common stock on February 11, with an estimated market value of approximately $3.84 million.
Reduction in Shareholding: Thomas has reduced his shareholding in Apogee Therapeutics by 80,000 shares since December 4, 2025, with a total value of around $6.13 million.
Apogee Therapeutics (APGE) Options Volume Surges 46.6% Today
- Active Options Trading: Apogee Therapeutics has seen an options volume of 4,166 contracts today, equating to approximately 416,600 shares, indicating a trading activity level of 46.6% of its average daily volume over the past month.
- High Demand Options: Notably, the $90 strike call option expiring on March 20, 2026, has seen a significant volume of 2,505 contracts traded today, representing about 250,500 shares, reflecting strong market interest at this strike price.
- Ceva Inc Options Activity: Concurrently, Ceva Inc has recorded an options volume of 1,294 contracts today, approximately 129,400 shares, which corresponds to 45.8% of its average daily trading volume over the past month.
- Increased Interest in Strike Price: Among Ceva's options, the $30 strike call option expiring on February 20, 2026, has seen a trading volume of 506 contracts today, representing around 50,600 shares, indicating a rising market focus on this strike price.
Stocks to Consider Buying in 2026: Insights from Our Roundtable Experts, Including DoorDash and LVMH
Stock Picks Overview: The second installment of the 2026 Barron’s Roundtable features 30 stock picks from five investment experts, highlighting both well-known companies and lesser-known options.
Familiar Names Included: Among the stock picks are recognizable brands such as Home Depot, Starbucks, and Nike, indicating a mix of established and emerging investment opportunities.
Biodegradable Innovation: The article hints at a British company that has recently acquired a manufacturer of biodegradable sneaker midsoles, showcasing a trend towards sustainable products in the footwear industry.
Investment Insights: The Roundtable serves as a platform for sharing diverse investment strategies and insights, appealing to both seasoned investors and those looking to explore new market trends.
Apogee Therapeutics CMO Sells $1.46 Million in Shares
- Share Sale: Carl Dambkowski, CMO of Apogee Therapeutics, sold 18,700 shares for approximately $1.46 million, reducing his direct holdings by 8.09% from 231,223 to 212,523 shares, indicating a structured liquidity management approach.
- Option Exercise: Prior to the sale, Dambkowski exercised 14,025 stock options, maintaining a substantial stake worth about $16.8 million, which reflects his ongoing confidence in the company's future prospects.
- Market Performance: Apogee Therapeutics shares have surged approximately 60% over the past year, significantly outperforming the S&P 500's 18% gain, indicating growing market confidence in its immunology pipeline and competitive positioning in the biotech sector.
- Financial Position: As of the third quarter, Apogee reported $913 million in cash and cash equivalents, ensuring funding through the second half of 2028, which supports its strategic development in clinical-stage biologics.
Apogee Therapeutics CMO Sells $1.46 Million in Shares Following Options Exercise
- Significant Transaction Size: Apogee Therapeutics' CMO Carl Dambkowski sold 18,700 shares for a total value of $1.46 million on Wednesday, which is substantially larger than his recent median sale size of 3,690 shares, highlighting the impact of the options exercise on transaction scale.
- Options Exercise and Sale: The transaction involved exercising 14,025 options and immediately selling 18,700 shares, indicating a structured liquidity event following a strong market performance rather than a signal of clinical confidence in the company.
- Stable Equity Holdings: Post-transaction, Dambkowski retains 212,523 shares valued at approximately $16.8 million, demonstrating continued confidence in the company despite the large sale.
- Company Financial Health: Apogee Therapeutics has a market capitalization of $5.3 billion and a 60% stock price increase over the past year, reflecting strong market confidence in its immunology pipeline, while closing the third quarter with $913 million in cash and equivalents, ensuring funding for future needs.
